ReviewRheumatology international2021
Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.
Review in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review.Rheumatology international · 2026Pooled it
- Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report.Clinical case reports · 2026Article
- Case Report: Eosinophilic fasciitis with PM-Scl antibody positivity: expanding the serological spectrum.Frontiers in medicine · 2026Article
- The utility of rituximab in patients with eosinophilic fasciitis: case series from an Australian tertiary multidisciplinary clinic.Clinical rheumatology · 2026Article
- Eosinophilic Fasciitis after Covid Infection: A Case Report and Review of Literature.Clinical medicine & research · 2025Review
- Treatment and Monitoring of Eosinophilic Fasciitis.Current treatment options in rheumatology · 2025Article
- Eosinophilic Fasciitis: A Case Series.Cureus · 2025Article
- Recurrent Eosinophilic Fasciitis: The First Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fasciitis?Mediterranean journal of rheumatology · 2023Review
- [Eosinophilic dermatoses].Dermatologie (Heidelberg, Germany) · 2022Article
- Eosinophilic cystitis mimicking hemorrhagic cystitis in relapsed follicular lymphoma.International cancer conference journal · 2022Article
- Eosinophilic fasciitis: unraveling the clinical tapestry of a rare case and review of literature.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key messageRTX could be an effective and safe alternative treatment for refractory EF. Rituximab (RTX) is a successful therapeutic option for various autoimmune diseases. Our aim is to report our experience with RTX in eosinophilic fasciitis (EF) and review published data on its efficacy for the treatment of EF. We reviewed the medical charts of all patients with a diagnosis of EF treated with RTX from 2008 to 2020 in the Department of Rheumatology and Clinical Immunology in the University Hospital of Heraklion, Crete, Greece. We also reviewed the English literature for cases of EF treated with RTX. Demographics, clinical manifestations, laboratory findings, prior treatments, response to RTX, cumulative RTX dose, duration of treatment and follow-up are reported. We report three cases of EF refractory to conventional DMARDs (cDMARDs) that responded to RTX. Furthermore, literature review revealed five cases. In our case series in all patients, RTX was the first biologic. RTX could be effective in cases of (EF) refractory to standard immunosuppressive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.